Skip to NavigationSkip to content


National Institutes of Health says COVID-19 patients should not take hydroxychloroquine

Photo from Pixarbay

Experts at the US National Institutes of Health (NIH) have drafted treatment guidelines for the use of hydroxychloroquine in COVID-19 patients, saying it should not be used due to “potential toxicities.”

In a statement released on their website, the NIH said: “The COVID-19 Treatment Guidelines Panel (the Panel) does not recommend the use of any agents for pre-exposure prophylaxis (PrEP) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outside of the setting of a clinical trial.

New Chinese study shows Hydroxychloroquine does not speed up COVID-19 recovery

Photo by Joegoauk Goa

The anti-malaria drug hydroxychloroquine does not speed up recovery from COVID-19, according to a new Chinese study.

The study was conducted by doctors across China, including Wuhan and Hubei, and tested 75 COVID-19 patients in hospitals and compared their illnesses to 75 patients who did not receive the drug. These patients received the medication for two or three weeks depending on how severe their symptoms were.'s weekly COVID-19 news round-up

Image credit: CDC

Hydroxychloroquine dominates the latest coronavirus news this week. The anti-malaria drug, touted by President Trump as an effective COVID-19 treatment, has proved dangerous in a clinical trial in Brazil. Since Trump has praised the drug there has been an increase in misuse across the US. Critics have also alleged the President's continuous messaging about the treatment is motivated by his small financial link to Sanofi.

Fatal heart complications halt Brazilian study of chloroquine in treating COVID-19

Photo by Joegoauk Goa

A chloroquine study investigating its effects in treating the COVID-19 coronavirus in Brazil has been postponed for safety reasons.

It was discovered that taking a higher dose of the drug made some patients develop irregular heart rates that increased their risk of a fatal heart arrhythmia.

US reports increase in Hydroxychloroquine misuse

Photo by Joegoauk Goa

The American Association of Poison Control Centers (AAPCC) has said there has been an increase in people abusing the anti-malaria drug hydroxychloroquine, after being touted by President Donald Trump as a coronavirus treatment.

Since Trump first mentioned the drug on 19 March, there have been 76 cases of hydroxychloroquine abuse compared to 35 during this same period last year. 77% of these cases were non-toxic meaning most patients taking the drug inappropriately were not poisoned. 

Critics say Trump pushing hydroxychloroquine due to his financial ties to manufacturers

Photo by Gage Skidmore

Critics are arguing that President Donald Trump is touting the malaria drug hydroxychloroquine as a COVID-19 treatment because he has financial links to manufacturers of the drug.

The New York Times reported that each of Trump’s three family trusts had investments in a Dodge & Cox mutual fund. This type of fund is a portfolio that pools together money from several investors and invests the capital across various assets like stocks and bonds.

Trump again tells people to take Hydroxychloroquine to treat COVID-19, despite a lack of evidence

Photo by Gage Skidmore

President Trump continues to push the drug hydroxychloroquine as a potential coronavirus treatment despite a lack of evidence for its effectiveness.

In a recent press conference, the President said: “I’m not looking at it one way or another. But we want to get out of this. If it does work, it would be a shame if we didn’t do it early. What do I know? I’m not a doctor. But I have common sense. The FDA feels good about it, as you know, they approved it.”

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches